Page 226 - 《精细化工》2022年第9期

·1944· 精细化工 FINE CHEMICALS 第 39 卷

总摩尔收率可达~38%。本工艺具有如下特点： [9] LU W Q, YU W W, HE J C, et al. Reprogramming immunosuppressive
（1）(S/R)-1-苯乙胺氨基上保护基与苯环对位溴 myeloid cells facilitates immunotherapy for colorectal cancer[J].
代一锅法反应中，保护基选择三氟乙酰基，对于后 EMBO Molecular Medicine, 2021, 13(1): 12798.
[10] STASI L P, BHIMANI K, BORRIELLO M, et al. Synthesis,
续的苯基对位溴代以及最后一锅法脱保护基都具有更
pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo
好的兼容性；在（0±2）℃下，当投料比为 n(DBDMH)/
[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists
n(Ⅱ)=0.55 时，可获得摩尔收率为 50.7%的对位溴代 of the prostaglandin EP4 receptor[J]. Bioorganic & Medicinal
产物Ⅲ；粗产品根据杂质实际情况，采用 V(无水甲 Chemistry Letters, 2011, 21(21): 6336-6340.
醇)/ V(水)=1 体系作为重结晶溶剂，可有效去除副产 [11] ELENA C, FRANCESCO C, TERESA D, et al. Heterocondensed
物，此工艺经过后续生产的验证，工艺稳定性较好， pyridones compounds and their use as IDH inhibitors:
收率及产品质量都较稳定。 WO2019224096A1[P]. 2019-11-28.
[12] YANG J. Iso-citrate dehydrogenase (IDH) inhibitor: WO2018010637A1[P].
（2）在中间体Ⅳ的合成过程中，考察了不同温
2018-01-18.
度、正丁基锂用量对苯基对位甲酸化反应的影响， [13] ZHANG S W, GONG C J, SU M B, et al. Synthesis and in vitro and
当投料比为 n(Ⅲ)∶n(正丁基锂)=1∶2.0，反应温度 in vivo biological evaluation of tissue-specific bisthiazole histone
低于–60 ℃，摩尔收率最高达到 90.9%，且工艺及 deacetylase (HDAC) inhibitors[J]. Journal of Medicinal Chemistry,
收率稳定。 2020, 63(2): 804-815.
（3）在终产物的合成过程中，首先通过对多种酸 [14] NAN F J, LI J, DING J, et al. Aryl-2,2'-tandem bisthiazole compound
and preparation method and use thereof: WO2018041004A1[P].
催化结果的对比，最终确定了氯化亚砜/无水甲醇条件
2018-03-08.
下一步完成羧基甲酯化和脱保护基，然后再对氯化亚
[15] TOSHIKI M, ENYU I. Preventives/remedies for kidney diseases:
砜用量及反应温度进行优化，在 65 ℃下，投料比为 WO2001074391A1[P]. 2001-10-11.
n(Ⅳ)∶n(氯化亚砜)=1∶3.0，摩尔收率可达 84.1%。 [16] MAKOTO N, HAJIME N, MASAYOSHI U. Preventives/remedies
总之，本工艺可以顺利放大用于生产(S/R)-4- for liver diseases: WO2000064478A1[P]. 2000-11-02.
(1-氨基)乙基苯甲酸甲酯盐酸盐，工艺稳定，操作简 [17] ELSA L, KLAUS D, MARCO S, et al. Small molecule bradykinin
B1 receptor antagonists: WO2009036996A2[P]. 2009-03-26.
便，总摩尔收率高达~38%，e.e.值>99%。
[18] CHRISTOPHER B, KENNETH M G, SEAN J H, et al. Substituted
参考文献： hydroxamic acid and uses thereof: WO2011106632[P]. 2011-09-01.
[19] SCHAUDT M, LOCARDI E, ZISCHINSKY G, et al. Novel small
[1] YANG J J, YU W W, HU L L, et al. Discovery and characterization
molecule bradykinin B1 receptor antagonists. Part 1: Benzamides and
of 1H-1,2,3-triazole derivatives as novel prostanoid EP4 receptor
semicarbazides[J]. Bioorganic & Medicinal Chemistry Letters, 2010,
antagonists for cancer immunotherapy[J]. Journal of Medicinal
20(3): 1225-1228.
Chemistry, 2020, 63(2): 569-590.
[2] ZHANG H K, LU W Q, LIU M Y, et al. Triazole compounds and [20] BOYD M J, BERTHELETTE C, CHIASSON J F, et al. A novel
their synthetic methods and applications: CN108929281A[P]. series of potent and selective EP4 receptor ligands: Facile modulation
2017-05-27. of agonism and antagonism[J]. Bioorganic & Medicinal Chemistry
[3] ANNE-LAURE B, ISMET D, GAEL H, et al. Prostaglandin Letters, 2011, 21(1): 484-487.
E2(PGE2) EP4 receptor antagonists: WO2021064189A2[P]. 2019- [21] WANG J (王娟), LI M L (李美玲), CHEN L G (陈立功), et al.
02-10. Synthesis of (S)-1-(1-phenylethyl)-4-piperidone[J]. Fine Chemicals
[4] JEREMY S Y. Phenoxyethyl dihydro-1H-isoquinoline compounds: (精细化工), 2007, 24(11): 1109-1111.
WO2014186218A1[P]. 2014-11-20.
[22] MUTULE I, SUNA E. Arylzinc species by microwave assisted
[5] ZHENG W J, ZHU X J, DU H, et al. EP4 antagonists:
grignard formation-transmetallation sequence: Application in the
WO2017066633A1[P]. 2017-04-20.
negishi coupling[J]. Tetrahedron, 2005, 61(47): 11168-11176.
[6] DINESH B, ANIL M D, SANTOSH P, et al. 1-Substituted 1,2,3,4-
[23] MONTEIL F, KALCK P. Carbonylation of bromobenzene in a
tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4
biphasic medium catalysed by water-soluble palladium complexes
receptor antagonists: WO2017014323A1[P]. 2017-01-26.
[7] OKUMURA Y, YAMAGISHI T, NUKUI S, et al. Discovery of derived from tris(3-sulphophenyl)phosphine[J]. Journal of Organometallic
AAT-008, a novel, potent, and selective prostaglandin EP4 receptor Chemistry, 1994, 482(1/2): 45-51.
antagonist[J]. Bioorganic & Medicinal Chemistry Letters, 2017, [24] WANG L, NEUMANN H, BELLER M. A general Pd-catalyzed
27(5): 1186-1192. synthesis of arylacetic and benzoic acids using formic acid without
[8] ANIL M D, DINESH B, SANTOSH P, et al. Heterocyclic compounds: activator[J]. Angewandte Chemie, International Edition, 2018, 57(23):
WO2016088903A1[P]. 2016-06-09. 6910-6914.